Thu Sep 19 06:23:17 UTC 2024: ## OPKO Health (OPK) Stock Receives “Buy” Rating from HC Wainwright

**Miami, FL – September 19, 2024** – OPKO Health (NASDAQ: OPK), a leading healthcare company specializing in diagnostics and pharmaceuticals, saw its stock receive a “buy” rating from equity research analysts at HC Wainwright, according to a report released on Tuesday. The firm has set a $3.00 price target for OPK, signifying a potential upside of 85.19% from the current market price.

This positive outlook follows a series of mixed ratings from other analysts. Barrington Research upgraded OPKO Health to an “outperform” rating and increased its price objective to $2.25, while StockNews.com downgraded the company to a “sell” rating. Piper Sandler lowered its target price to $3.00 but maintained an “overweight” rating.

OPKO Health’s recent earnings report, released on August 7th, showed a positive beat on earnings per share, surpassing analysts’ estimates. The company reported ($0.01) EPS for the quarter, exceeding the predicted ($0.09) by $0.08. While revenue fell short of estimates at $182.20 million compared to $184.70 million, the company experienced a significant decline in revenue year-over-year.

Insider activity has also been notable, with Opko Health, Inc., a major shareholder, selling 14,082 shares of OPKO Health stock in a transaction on July 3rd. This sale, however, was offset by increased institutional investor activity, with several firms purchasing new stakes in OPKO Health during recent quarters.

OPKO Health, Inc. operates in the diagnostics and pharmaceuticals sectors, offering laboratory testing services, molecular diagnostics, and its flagship 4Kscore prostate cancer test. The company’s strong focus on diagnostics and its ongoing pharmaceutical endeavors are key factors driving investor interest.

**Disclaimer:** This news article is based on publicly available information and should not be considered investment advice. Investors are advised to conduct their own research and consult with a financial professional before making any investment decisions.

Read More